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Abstract
Background & Aims: The accuracy of noninvasive tools for the diagnosis of
severe fibrosis in patients with nonalcoholic fatty liver disease(NAFLD) in
clinical practice is still limited. We aimed at assessing the diagnostic perfor-
mance of combined noninvasive tools in two independent cohorts of Italian
NAFLD patients. Methods: We analysed data from 321 Italian patients(179
Sicilian-training cohort, and 142 northern Italy-validation cohort) with an
histological diagnosis of NAFLD. Severe fibrosis was defined as fibrosis ≥ F3
according to Kleiner classification. The APRI, AST/ALT, BARD, FIB-4, and
NFS scores were calculated according to published algorithms. Liver stiffness
measurement(LSM) was performed by FibroScan. Cut-off points of LSM,
NFS and FIB-4 for rule-in or rule-out F3-F4 fibrosis were calculated by the
reported formulas. Results: In the Sicilian cohort AUCs of LSM, NFS, FIB-4,
LSM plus NFS, LSM plus FIB-4, and NFS plus FIB-4 were 0.857, 0.803,
0.790, 0.878, 0.888 and 0.807, respectively, while in the northern Italy cohort
the corresponding AUCs were 0.848, 0.730, 0.703, 0.844, 0.850, and 0.733
respectively. In the training cohort, the combination of LSM plus NFS was
the best performing strategy, providing false positive, false negative and
uncertainty area rates of 0%,1.1% and 48% respectively. Similar results were
obtained in the validation cohort with false positive, false negative and uncer-
tainty area rates of 0%,7.3% and 40.8%. Conclusions: The combination of
LSM with NFS, two complementary, easy-to-perform, and widely available
tools, is able to accurately diagnose or exclude the presence of severe liver
fibrosis, also reducing of about 50–60% the number of needed diagnostic
liver biopsies.
Nonalcoholic fatty liver disease (NAFLD), the hepatic
manifestation of insulin resistance (IR), is a growing
cause of chronic liver disease worldwide with a preva-
lence of about 20–30% in the general population (1).
The clinical relevance of NAFLD stems from the evi-
dence that a relevant proportion of patients, especially
those with nonalcoholic steatohepatitis (NASH), may
develop cirrhosis and its complications (1, 2). The
most significant risk factors for disease progression are
the degree of liver damage and of metabolic impair-
ment, and a recent revision (3) clearly underlined that
baseline severity of liver fibrosis is the strongest deter-
minant of liver and non-liver-related mortality in NA-
FLD patients. Liver biopsy, albeit invasive, painful and
with potentially life-threatening complications (4), is
currently the gold standard for diagnosing advanced
fibrosis in patients with NAFLD but is impractical for
widespread use as a prognostic tool. In the last years
the need for a robust and economical population-based
screening to identify individuals with advanced fibrosis
has led to the development of several noninvasive, bio-
chemical and instrumental tools, but results are con-
trasting and large areas of diagnostic uncertainty are
left (5–7). Specifically, AST/ALT ratio, APRI, BARD,
FIB-4 and NAFLD fibrosis score (NFS) are easy and†Both these authors contributed equally to this study.
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quite reliable scores to be used in clinical practice (8–
12), (13) while liver stiffness measurement (LSM) using
transient elastography (TE) is probably the most vali-
dated tool to assess the stage of fibrosis not only in
CHC and NAFLD patients (14–19). The main target of
all the afore-mentioned noninvasive tools should be
the accurate prediction of severe liver fibrosis with low
rates of false positive and false negative results, thus
reducing the need for diagnostic liver biopsy, but each
of them bears potential limitations. Our aim was to
assess the performance of combined noninvasive tools
for identifying advanced fibrosis in a cohort of consec-
utive patients with biopsy-proven NAFLD from Sicily
and to validate the results in another independent
cohort from northern Italy.
Materials and methods
Patients
We retrospectively analysed data from Italian patients
with a clinical and histological diagnosis of NAFLD,
arising from two referral centres for liver diseases.
The study cohort included 205 patients prospectively
recruited at the Gastrointestinal & Liver Unit of the
Palermo University Hospital (training set), and 220
patients recruited at the Gastro-hepatology Division
of the University Hospital Torino (validation set). 26
patients (12.7%) from the Sicilian, and 52 (23%)
from the northern Italy cohort were failure to a valid
LSM because of obesity or unavailable results.
Accordingly, all analyses were performed on 321
patients (179 from Sicily, and 142 from northern
Italy) with complete biochemical data and LSM
availability.
Other causes of liver disease were ruled out, includ-
ing alcohol intake (>20 g/day) evaluated by a question-
naire, viral and autoimmune hepatitis, hereditary
haemochromatosis, and alpha1-antitrypsin deficiency.
Patients with advanced cirrhosis, hepatocellular carci-
noma, and current use of steatosis inducing drugs were
excluded.
This study was carried out in accordance with the
principles of the Helsinki Declaration and its appendi-
ces, and with local and national laws. Approval was
obtained from the hospital Internal Review Boards and
their Ethics Committees, and written informed consent
for the study was got from all the patients.
Clinical, laboratory assessment, and histology
Clinical and anthropometric data, including BMI, the
presence of arterial hypertension, impaired fasting glu-
cose (IFG), and type 2 diabetes, were collected at the
time of enrolment. On the same day of liver biopsy, a
12-hour overnight fasting blood sample was drawn to
determine serum levels of AST, ALT, PLT, albumin,
total, HDL and LDL-cholesterol, triglycerides, plasma
glucose concentration and insulin. Insulin resistance
was calculated by the homoeostasis model assessment
(HOMA) (20).
Histological slides were coded and read at each clini-
cal centre by one expert pathologist, who was unaware
of patients’ identity and history. A minimum 15 mm-
length of the biopsy specimen or the presence of at least
ten complete portal tracts was required (21). Steatosis
was assessed as the percentage of hepatocytes containing
fat droplets (minimum 5%), and evaluated as a continu-
ous variable. Kleiner classification (22) was used to
compute steatosis and lobular inflammation, and to
stage fibrosis from 0 to 4.
Noninvasive fibrosis algorithms/tools
The APRI (AST, PLT), AST/ALT ratio (AST, ALT),
BARD (BMI, AST, ALT, Diabetes), FIB-4 (age, AST,
ALT, PLT) and NFS (age, IFG/Diabetes, BMI, PLT,
albumin, AST/ALT) were calculated using the original
reported formulas (8–12).
Transient elastography was performed by FibroScan
(Echosens, Paris, France) medical device using the M
probe. LSM was assessed on the same day of liver
biopsy, before the procedure, by one expert operator
who had previously done at least 100 determinations in
patients with chronic liver disease. LSM was expressed
in kilopascal (kPa) and calculated as the median value
of ten successful acquisitions, defined by a success rate
of at least 60%, and by an interquartile range lower than
30% as previously described (23) and as suggested by
the manufacturing company.
Statistics
Continuous variables were summarized as mean  SD,
and categorical variables as frequency and percentage.
The accuracy of each score and of their combinations
for detection of severe fibrosis (F3–F4) was assessed
using receiver operator characteristic curves described
as AUC with 95% confidence intervals (95% CI). A
patient was assessed as positive or negative according to
whether the noninvasive marker value was greater than,
less than, or equal to a given cut-off value. Connected
with any cut-off value is the probability of a true posi-
tive (sensitivity) and the probability of a true negative
(specificity). AUCs are compared using DeLongs test.
Cut-off points of LSM, NFS and FIB-4 for the F3–F4
model were derived from literature. Specifically, for
LSM, cut-offs of <7.9 KPa and of ≥9.6 KPa were used to
rule-out and rule-in, respectively, severe fibrosis (15);
for NFS, cut-offs of <1.455 and of >0.676 were used to
rule-out and rule-in, respectively, severe fibrosis (8);
and for FIB-4, cut-offs of <1.30 KPa and of >2.67 were
used to rule-out and rule-in, respectively, severe fibrosis
(7). Accordingly, false negative and false positive rates
of the single test, and of their combination, as well as
sensitivity, specificity, positive likelihood ratio (LHR),
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negative LHR, positive predictive value (PPV), and neg-
ative predictive value (NPV) are calculated.
Analysis was performed by SPSS 18.0.3, and by MED-
CALC.
Results
Patient characteristics and histology
The baseline features of the 179 Sicilian (training set)
and of the 142 northern Italian (validation set) NAFLD
patients are shown in Table 1. Aminotransaminase lev-
els tended to be mildly elevated with 60.9% in the train-
ing, and 64.1% in the validation cohorts; ALT was
generally less than twice the upper limit of normal, and
within the normal range in 12.8% and 20.4% of the
cases respectively. The patient characteristics were
slightly different between institutions (Table 1). Patients
from Sicily were more likely to have obesity, hyperten-
sion and more severe lobular inflammation compared
to northern Italian patients. The mean length of the liver
fragments given for histology was 17 mm (range 15–31)
for Sicilian patients, and 20 mm (range 15–40) for
northern Italy patients. Histological staging was similar
in the two cohorts and significant fibrosis (F3–4) was
present in one out of five patients.
Diagnostic performance of single noninvasive tools for the
diagnosis of severe liver fibrosis
Figures 1A and B show the accuracy, in terms of AUC,
of the different noninvasive tools to detect fibrosis ≥ F3
in both the training and validation cohorts. In the train-
ing cohort the three best performing noninvasive tools
were LSM, NFS and FIB-4 with AUC values of 0.857,
0.803, and 0.790 respectively. Accordingly, The AUC
value of LSM was significantly higher than those of
BARD score (P = 0.002), APRI (P = 0.003), and AST/
ALT ratio (P < 0.001), the AUC of NFS was signifi-
cantly higher than those of BARD (P = 0.02), APRI
(P = 0.04), AST/ALT (P = 0.01), and the AUC of FIB-4
significantly higher than those of APRI (P = 0.007) and
Table 1. Baseline demographic, laboratory, metabolic, and histological features of 321 Italian patients with nonalcoholic fatty liver disease
Nonalcoholic fatty liver Nonalcoholic fatty liver disease
Variable disease (Sicily n = 179) (northern Italy n = 142) P value
Mean age – years 45.4  13.3 (18–72) 43.9  11.8 (18-–78) 0.29
Male gender 121 (67.5) 102 (71.8) 0.41
Mean body mass index – kg/m2 29.3  4.1 (18.8–41.6) 27.4  3.7 (15.7–37.4) <0.001
Body mass index – kg/m2
<25 20 (11.1) 34 (23.9)
25–29.9 84 (46.9) 74 (52.2)
≥30 75 (41.8) 34 (23.9) 0.001
Aspartate aminotransferase – IU/ml 45.7  32.5 (15–290) 42.2  24.4 (12–198) 0.29
Alanine Aminotransferase – IU/ml 80.3  53.6 (17–453) 75.6  45.8 (13–323) 0.40
Platelets – 103/mmc 221.5  61.5 (65–418) 230.2  70.0 (71–664) 0.23
Albumin – g/dl 4.6  0.3 (3.8–5.4) 4.6  0.4 (3.2–5.3) 0.23
Total bilirubin – mg/dl 0.6  0.3 (0.1–3.0) 0.6  0.3 (0.3–3.1) 0.23
INR 0.9  0.1 (0.8–2.0) 0.9  0.1 (0.8–2.0) 0.23
Arterial hypertension 43 (24.0) 17 (11.9) 0.008
Impaired fasting glucose 49 (27.3) 58 (40.8) 0.01
Type 2 diabetes 35 (19.5) 22 (15.4) 0.34
Cholesterol –mg/dl 206.2  47.6 (91–368) 205.3  46.9 (97–382) 0.86
HDL cholesterol –mg/dl 49.5  18.9 (18–175) 49.0  13.1 (24–113) 0.79
Triglycerides – mg/dl 149.5  83.1 (31–477) 153.7  104.4 (17–701) 0.69
Blood glucose – mg/dl 98.5  28.4 (64–307) 99.2  25.7 (70–245) 0.83
Insulin – lU/ml 16.5  10.3 (2.5–59.8) 16.8  17.6 (2–135) 0.81
HOMA Score 4.20  3.38 (0.40–21.5) 4.38  6.38 (0.36–53.5) 0.74
Liver stiffness measurement (KPa) 9.0  7.0 (3–63) 8.2  5.2 (3–38) 0.24
Histology
Lobular inflammation
0–1 vs. 2–3 74 (41.3) 7 (4.9) <0.001
Steatosis grade
1 (5–33%) 63 (35.1) 82 (58.7)
2 (>33–66%) 64 (35.8) 44 (31.7)
3 (>66%) 52 (29.1) 16 (9.6) <0.001
Stage of Fibrosis
3–4 41 (22.9) 29 (20.4) 0.59
Abbreviation: IU, international units; HOMA, homoeostasis model assessment; HDL, high density lipoprotein. Data are given as mean  standard
deviation (range), or as number of cases (%).
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AST/ALT (P = 0.006). In the replication cohort the
AUC values of LSM, NFS and FIB-4 were 0.848, 0.730,
and 0.703 respectively. In addition, their AUCs were sig-
nificantly higher than that of AST/ALT ratio (P < 0.001,
P = 0.03, and P = 0.03 respectively), and the AUC of
LSM was better than FIB-4 (P = 0.03).
In view of the results in the training set, only LSM,
FIB-4 and NFS scores were further analysed for diagnos-
tic performance by using cut-offs previously reported in
the literature to rule-in and rule-out F3-F4 fibrosis
(7.9 KPa and 9.6 KPa for LSM, 1.30 and 2.67 for FIB-4,
and 1.455 and 0.676 for NFS). Thus, in the training
and validation cohorts, NFS provided the highest speci-
ficity (99.1% and 100% respectively), highest PPV
(85.7% and 100% respectively) and highest positive
LHR (37.3 and infinity respectively), while LSM had the
highest sensitivity (85.3% and 68% respectively), highest
NPV (95.2% and 91.2% respectively) and lowest nega-
tive LHR (0.2 and 0.3 respectively) (Table 2). In both
the training and the validation cohorts, NFS had the
lowest false positive rates (14.2% and 0% respectively),
while LSM showed the lowest false negative rates (4.7%
and 8.7% respectively) (Table 2). Interestingly, elevated
ALT levels (ALT>100) (24) explained the 15.4% (2/13)
and the 34.8% (8/23) of the false positive results of LSM
in Sicilian and northern Italy cohorts respectively.
Diagnostic performance of combined noninvasive tools
for the diagnosis of severe liver fibrosis
We finally evaluated the performance of paired combi-
nations of LSM, NFS and FIB-4 for the diagnosis of
severe liver fibrosis (≥ F3) in both cohorts.
In the training cohort, the AUCs of the tested combi-
nations were 0.878, 0.888 and 0.807 for LSM plus NFS,
LSM plus FIB-4, and NFS plus FIB-4 respectively
(Fig. 1C). Both LSM plus NFS, and LSM plus FIB-4,
were superior to NFS plus FIB-4 (P = 0.03 for both).
LSM plus NFS had an AUC higher compared to FIB-4
(P = 0.01) and NFS (P = 0.02), as well as LSM plus
FIB-4 compared to FIB-4 (P = 0.006) and to NFS
(P = 0.04). Similar results were obtained in the replica-
tion cohort, where LSM plus NFS, LSM plus FIB-4, and
NFS plus FIB-4 had AUCs of 0.844, 0.850, and 0.745
respectively (Fig. 1D). Both LSM plus NFS, and LSM
plus FIB-4, performed better than NFS (P = 0.03 for
both), FIB-4 (P = 0.03 and P = 0.02 respectively), and
NFS plus FIB-4 (P = 0.04 and P = 0.03 respectively).
(A)
(C) (D)
(B)LSM
Fig. 1. Receiver operating characteristic (ROC) curve for singular and combined noninvasive tools on the basis of the presence of F3–F4
fibrosis. (A) ROC curve for APRI (AUC 0.688, 95% C.I. 0.593–0.783), AST/ALT (AUC 0.685, 95% C.I. 0.595–0.775), BARD (AUC 0.717,
95% C.I. 0.629–0.805), FIB4 (AUC 0.790, P5% C.I. 0.705–0.875), NFS (AUC 0.803, 95% C.I. 0.711–0.894), and liver stiffness measurement
(LSM) (AUC 0.857, 95% C.I. 0.790–0.924) in the 179 Sicilian patients. The AUC value of LSM was significantly higher than those of BARD
score (P = 0.002), APRI (P = 0.003), and AST/ALT ratio (P < 0.001); the AUC of NFS was significantly higher than those of BARD (P = 0.02),
APRI (P = 0.04), AST/ALT (P = 0.01), and the AUC of FIB-4 significantly higher than those of APRI (P = 0.007) and AST/ALT (P = 0.006). (B)
ROC curve for APRI (AUC 0.746, 95% C.I. 0.641–0.850), AST/ALT (AUC 0.597, 95% C.I. 0.472–0.723), BARD (AUC 0.803, 95% C.I.
0.723–0.882), FIB4 (AUC 0.703, 95% C.I. 0.589–0.816), NFS (AUC 0.730, 95% C.I. 0.621–0.838), and LSM (AUC 0.848, 95% C.I. 0.774–
0.922) in the 142 northern Italy patients. The AUCs of LSM, NFS and FIB-4 were significantly higher than that of AST/ALT ratio (P < 0.001,
P = 0.03, and P = 0.03 respectively), and the AUC of LSM was better than FIB-4 (P = 0.03). (C) ROC curve for LSM plus NFS (AUC 0.878,
95% C.I. 0.821–0.936), LSM plus FIB4 (AUC 0.888, 95% C.I. 0.836–0.941), and NFS plus FIB4 (AUC 0.807, 95% C.I. 0.719–0.895) in the
179 Sicilian patients. Both LSM plus NFS, and LSM plus FIB-4, were superior to NFS plus FIB-4 (P = 0.03 for both). LSM plus NFS had an AUC
higher compared to FIB-4 (P = 0.01) and NFS (P = 0.02, as well as LSM plus FIB-4 compared to FIB-4 (P = 0.006) and to NFS (P = 0.04). (D)
ROC curve for LSM plus NFS (AUC 0. 844, 95% C.I. 0.766–0.923), LSM plus FIB4 (AUC 0.850, 95% C.I. 0.777–0.922), and NFS plus FIB4
(AUC 0.733, 95% C.I.0.626–0.841) in the 142 northern Italy patients. Both LSM plus NFS, and LSM plus FIB-4, performed better than NFS
(P = 0.03 for both), FIB-4 (P = 0.03 and P = 0.02 respectively), and NFS plus FIB-4 (P = 0.04 and P = 0.03 respectively).
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In the training cohort, overall LSM plus NFS was the
best performing combination strategy with specificity
and PPV of 100%, and with sensitivity, NPV and nega-
tive LHR of 83.3%, 98.9% and 0.1 respectively (Table 2,
upper panel). Similar results were observed in the vali-
dation cohort, where LSM plus NFS provided specificity
and PPV of 100%, and sensitivity, NPV and negative
LHR of 25%, 92.7% and 0.7% respectively (Table 2,
bottom panel). Accordingly, both in the training and
validation cohorts, LSM plus NFS had the lowest false
positive (0% for both), and false negative rates (1.1%
and 7.3% respectively) (Table 2 and Fig. 2).
Discussion
Nonalcholic fatty liver disease, with an estimated preva-
lence around 25% in the general population (1), is
becoming the leading cause of chronic liver diseases
worldwide and its liver-related prognosis is finally
decided by the amount of liver fibrosis accumulating
over the years (3). The noninvasive identification of
NAFLD patients at high risk for advanced liver disease
who may benefit from more intensive management is
still an unmet need. In this study, including NAFLD
cohorts from two different centres as training and vali-
dation set respectively, we found that the combination
of biochemical (NFS) with instrumental (LSM) nonin-
vasive tools can significantly improve the diagnostic
accuracy of severe liver fibrosis, by reducing the rates of
false positive and particularly false negative results.
Similarly to other studies, we confirmed LSM and
NFS, together with FIB-4 score, as the best performing
single noninvasive tools for the diagnosis of severe liver
fibrosis in NAFLD, with an acceptable/good diagnostic
ability according to AUC values. However, when evalu-
ating the performance of each score to rule-in or rule-
out severe liver fibrosis, we observed high rates of false
negative –for NFS and FIB-4-, and false positive –for
LSM- results, in both cohorts. Specifically, lower false
negative (up to 4.7%), but higher false positive (up to
LSM <7.9 Kpa
and
NFS <–1.455
(rule-out F3-F4 fibrosis)
N = 88
No Liver Biopsy
1/88 (1.1%) false negative
with F3-F4 fibrosis 
LSM ≥9.6 Kpa
and
NFS >0.676
(rule-in F3-F4 fibrosis)
N = 5
Discordant
N = 86
No Liver Biopsy
0/5 (0%) false positive
without F3-F4 fibrosis 
Liver Biopsy
179 Sicilian NAFLD Patients
LSM <7.9 Kpa
and
NFS <–1.455
(rule-out F3-F4 fibrosis)
N = 82
No Liver Biopsy
6/82 (7.3%) false negative
with F3-F4 fibrosis 
LSM ≥9.6 Kpa
and
NFS >0.676
(rule-in F3-F4 fibrosis)
N = 2
Discordant
N = 58
No Liver Biopsy
0/2 (0%) false positive
without F3-F4 fibrosis 
Liver Biopsy
142 Northern Italy NAFLD Patients
(A)
(B)
Fig. 2. False positive results, false negative results, and uncertainty area using combined noninvasive tools. (A) Liver stiffness measurement
plus NFS for Sicilian cohort; (B) Liver stiffness measurement plus NFS for northern Italy cohort.
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44.2%) rates were observed for LSM, while false positive
rates for NFS were ranging from 0% in northern Italy to
14.2% in Sicilian cohort. Our data confirm the modest
overall accuracy of the single noninvasive tools, and
therefore the impossibility to rely on just one of them in
clinical practice (5–17).
The applicability of single noninvasive tools is an
important issue also in patients with chronic hepatitis
C. In this clinical setting, recent studies showed that the
combination of two noninvasive tools could help to
generate algorithms with a higher diagnostic accuracy,
thus limiting the number of liver biopsies (23, 25). The
better performance of multiple vs. single tests is also
confirmed in our study, particularly by the combination
of LSM (an instrumental tool at low false positive
results) with NFS (a clinical-biochemical tool at high
false negative results), since this approach is able to
reduce both false negative (range 1.1–7.3%) and false
positive (0%) results, although increasing the number of
patients in the ‘uncertainty area’. The advantage of this
approach is better evident in the Sicilian than in the
northern Italy cohort, where false negative rates are only
slightly improved. Whenever LSM would be nonreli-
able/available, then the combination of two clinical-
biochemical tools (NFS and FIB-4) can reduce false
positive results (at least in the Sicilian cohort), obtaining
a similar false negative rate. The worse performance of
combination strategies in northern Italy patients is
probably because of the better performance of NFS in
this cohort.
This study has limitations. First, it is aimed at opti-
mizing the use of currently easy-to-perform and widely
available noninvasive tools for NAFLD patients, even if,
while clinical-biochemical scores are ever available, LSM
could not be. In addition, we cannot rule out that the
introduction of new techniques/tools such as ARFI (26),
citokeratin-18 fragments serum levels (27), etc. could
improve the performance of the proposed combination.
Another methodological question is the potentially lim-
ited validity of the results in different populations and
settings. Our study included two cohorts of Italian
patients enrolled at tertiary care centres, and that are
different in terms of prevalence of obesity, steatosis and
liver inflammation. This issue could affect the interpre-
tation of our results, even if the similar performance of
the tested scores in the two population is a strength of
our work. In any case our tested populations may be
different from the majority of cases of NAFLD in the
general population. Thus, it is plausible that the
performance of the proposed algorithms could change
according to the clinical, biochemical and metabolic
characteristics of patients, and to the prevalence of
severe fibrosis. In this line, to strength our study, in our
analysis we used published standardized cut-offs and
not cut-offs calculated from data of our populations,
even if similar diagnostic performances were observed
in both the two scenarios (data not shown). In addition,
because of the complexity of NAFLD, the decision to
perform the liver biopsy must take into account not
only algorithms aimed to identify at risk patients, but
also a complete evaluation of pros and contra of liver
biopsy in the singular patient. Finally, the accuracy of
liver biopsy is always a methodological issue in this kind
of studies, related to sampling errors, technical process-
ing of the specimens, and interobserver variability and
both to the length of biopsy specimens and the number
of portal spaces. However, we are confident that the
minimum length of 15 mm and the presence of at least
ten complete portal tracts minimize this bias.
In conclusion, we demonstrated that the combina-
tion of LSM with NFS, two complementary, easy-to-
perform, and widely available tools, is able to accu-
rately diagnose or exclude the presence of severe liver
fibrosis, also reducing of about 50–60% the number
of needed diagnostic liver biopsies. From a clinical
standpoint, whenever LSM would be no reliable/avail-
able, we suggest to use the association between FIB-4
and NFS, characterized by an acceptable diagnostic
performance. Therefore, to reduce the proportion of
patients requiring liver biopsy to further stage the
disease, it may be possible to develop an algorithm
for investigation of patients with NAFLD that uses
simple noninvasive tests as recently observed for NFS,
APRI and FIB-4 in a large cohort of clinically diag-
nosed NAFLD patients (28). However, such an algo-
rithm will need to be carefully evaluated in a
prospective study.
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